Skip to content
preclinicalImmune & Inflammation

Thymosin Beta-15

Also known as: Tβ15, TB15, Thymosin β15, TMSB15A

Thymosin Beta-15 is a small actin-binding peptide in the beta-thymosin family that has gained research attention primarily as a cancer biomarker. It is overexpressed in aggressive tumors including prostate, breast, and lung cancers, where its levels correlate with metastatic potential and poor prognosis. Unlike its cousin Thymosin Beta-4, TB-15 has no established therapeutic use and is studied principally for its diagnostic and prognostic value in oncology.

3 cited references·4 researched benefits

Quick Answer

Thymosin Beta-15 is a small actin-binding peptide overexpressed in aggressive cancers including prostate, breast, and lung tumors. Its elevated levels correlate with increased metastatic potential and poor patient prognosis, making it a candidate cancer biomarker. Unlike Thymosin Beta-4, which is studied for tissue repair, TB-15 research focuses on its role in tumor cell motility and invasion. It remains in the preclinical research stage with no therapeutic applications.

Key Facts

Mechanism
Thymosin Beta-15 sequesters monomeric G-actin, modulating actin polymerization dynamics in tumor cells. Overexpression increases cellular motility by altering the actin cytoskeleton, facilitating cancer cell migration and invasion through extracellular matrices. It upregulates matrix metalloproteinases (MMPs) and promotes epithelial-to-mesenchymal transition (EMT) markers, contributing to metastatic behavior. In prostate cancer cells, TB-15 expression is driven by androgen receptor signaling and correlates with Gleason grade progression.
Research Status
preclinical
Half-Life
Not well characterized (intracellular protein)
Molecular Formula
C₂₁₅H₃₃₉N₅₇O₇₁S₂
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Potential diagnostic biomarker for aggressive prostate cancer — levels correlate with Gleason grade and metastatic riskmoderate
  • Prognostic marker in breast cancer — overexpression in tumor tissue associated with reduced disease-free survivalpreliminary
  • May serve as a therapeutic target — knockdown of TB-15 reduces tumor cell motility and invasion in vitropreliminary
  • Urinary biomarker candidate for non-invasive prostate cancer detectionpreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Not applicableN/AN/AThymosin Beta-15 is not used therapeutically. It is measured as a biomarker in tissue samples and body fluids for cancer diagnosis and prognosis.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Not applicable — Thymosin Beta-15 is studied as a biomarker, not administered therapeuticallycommon
  • Overexpression in tumors is associated with increased metastatic potential (endogenous pathological effect)serious

Frequently Asked Questions

What is the difference between Thymosin Beta-15 and Thymosin Beta-4?
Both belong to the beta-thymosin family and bind monomeric actin, but they have very different research profiles. Thymosin Beta-4 is studied as a therapeutic peptide for tissue repair, wound healing, and cardiac regeneration, with Phase 2 clinical trials completed. Thymosin Beta-15 is studied exclusively as a cancer biomarker — its overexpression in tumors correlates with aggressive behavior and metastatic potential. TB-15 is not used therapeutically.
Can Thymosin Beta-15 be used to detect prostate cancer?
Research suggests that Thymosin Beta-15 levels in prostate tumor tissue and urine correlate with cancer aggressiveness. Studies have shown that TB-15 expression increases with Gleason grade and is higher in metastatic compared to localized prostate cancer. However, it has not been validated as a standalone clinical diagnostic test and is not currently used in routine clinical practice. More research is needed to establish its utility alongside PSA and other biomarkers.
Is Thymosin Beta-15 available as a supplement or injection?
No. Thymosin Beta-15 is not available as a supplement, injection, or any therapeutic product. It is an intracellular protein studied in laboratory and clinical research settings as a cancer biomarker. Given that its overexpression promotes tumor cell motility and invasion, exogenous administration would be counterproductive and potentially harmful. Research interest lies in measuring its levels for diagnosis, not in administering it.

References

  1. 1
    Thymosin beta-15: a new molecule in prostate cancer progression(1998)PubMed ↗
  2. 2
    Thymosin beta-15 expression in tumor cell lines with varying metastatic potential(2003)PubMed ↗
  3. 3
    Beta-thymosins and cancer: implications for diagnosis and therapy(2007)PubMed ↗

Latest Research

Last updated: 2026-02-19